A phase II trial of the efficacy of tocilizumab in patients with resectable esophageal adenocarcinoma grouped for stromal activatio

Phase 1

• Conditions: oesophageal adenocarcinoma; Therapeutic area: Diseases [C] - Cancer [C04]

• Registration Number: EUCTR2020-002909-25-NL
• Lead Sponsor: Amsterdam University Medical Centers

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2020-10-07
• Last Update Posted: 21 June 2021

Recruitment & Eligibility

• Status: Authorised-recruitment may be ongoing or finished
• Sex: All
• Target Recruitment: 48

Inclusion Criteria

- Histologically proven adenocarcinoma of the esophagus or gastroesophageal junction.
- Surgically resectable (- Patient is fit for surgery

Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 24
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 24

Exclusion Criteria

-Past (within 5 years) or current history of malignancy other than entry diagnosis interfering with prognosis of esophageal cancer, not including superficial and adequately treated skin and cervical malignancies.

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified